Top Industry Leaders in the Chronic Kidney Disease Market
Latest Chronic Kidney Disease Companies Updates:
Ardelyx Receives FDA Approval for Xphozah (fosdenopterin): This drug treats hyperphosphatemia, a common complication in CKD patients, offering a new treatment option and potentially improving patient outcomes.
Bayer Introduces Kerendia (finerenone) in India: This drug, touted as a potential blockbuster for CKD, is the first SGLT2 inhibitor specifically approved for CKD. Its introduction in a major market like India expands access and treatment options for patients.
Roche and Genmab Partner on Novel Kidney Disease Treatment: The collaboration aims to develop a drug targeting a specific protein involved in CKD progression, offering a potential breakthrough therapy.
List of Chronic Kidney Disease companies in the market:
-
Abbott (US)
-
Siemens (Germany)
-
Beckman Coulter (US)
-
F. Hoffmann-La Roche Ltd (Switzerland)
-
ACON Laboratories, Inc (US)
-
Nova Biomedical (US)
-
ARKRAY (Japan)
-
AstraZeneca (UK)
-
GlaxoSmithKline Plc (UK)
-
Bayer AG (Germany)